PDCD1 and melanoma: We will use two-sample Mendelian randomisation to investigate the effect of genetically proxied levels of protein targets of two immune checkpoint inhibitors—programmed cell death protein 1 and programmed death ligand 1—on survival of seven cancer types (breast, colorectal, head and neck, lung, melanoma, ovarian and prostate).